Introduction {#Sec1}
============

Eosinophils are terminally differentiated cells of the myeloid lineage implicated in the pathogenesis of numerous inflammatory processes^[@CR1]^. In response to a variety of stimuli, mature peripheral blood eosinophils are recruited into the tissue, where they modulate immune responses through multiple mechanisms. Eosinophils secrete a series of cytokines capable of promoting T cell expansion, and T helper type 1 (Th1)/2 (Th2) polarization^[@CR2]^. Eosinophilia is defined as an elevation of eosinophils in the bloodstream. Many diseases are associated with eosinophilia, including parasitic diseases, allergy, autoimmune diseases, malignancy, primary hypereosinophilic syndrome^[@CR3]^.

Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized chronic fibroinflammatory disorder with multiple organ involvement, including salivary glands, lacrimal glands, pancreas, retroperitoneum, kidneys, lymph nodes, lungs, and liver among others. IgG4-RD is pathologically characterized by IgG4-positive lymphoplasmacytic infiltration, storiform fibrosis and obliterative phlebitis^[@CR4]^. The pathogenesis of IgG4-RD remains poorly understood.

Recently, eosinophilia had been reported to be associated with IgG4-RD to varying degrees (11--38%)^[@CR5]--[@CR11]^. This eosinophilia appeared inherent to the IgG4-RD rather than atopic disease^[@CR10],[@CR11]^. Some patients with high eosinophils as the first manifestation were finally confirmed to be IgG4-RD^[@CR12]--[@CR14]^. Eosinophils also infiltrate in the involved tissues, which is generally mild to moderate but can be remarkable in some cases^[@CR15]^. Eosinophilic angiocentric fibrosis was recently described as a form of IgG4-related systemic disease^[@CR16]^. In 2010, Sah *et al*. reported a similar clinical profile in type 1 autoimmune pancreatitis patients with and without peripheral eosinophilia^[@CR11]^. In 2014, Della-Torre *et al*. reported that there was a positive correlation between eosinophil count and serum IgG4^[@CR10]^. In 2017, Culver *et al*. revealed that eosinophil count was positively correlated with both serum IgE and serum IgG4. However, there was no statistical difference in serum IgG4 levels between IgG4-RD patients with and without eosinophilia^[@CR7]^.

In this study, we investigated the prevalence of eosinophilia in IgG4-RD patients in the largest prospective IgG4-RD cohort in China, and report here for the first time that patients with eosinophilia presented with significantly different clinical patterns in comparison to those with normal peripheral eosinophil count.

Results {#Sec2}
=======

Patients with eosinophilia showed male predominance and longer disease duration {#Sec3}
-------------------------------------------------------------------------------

Among 425 patients in this cohort, the median blood eosinophil count was 210 cells per μL (IQR 100--420; Table [1](#Tab1){ref-type="table"}). Eighty-seven patients (20%) showed peripheral blood eosinophil count higher than 500 per μL (0.5 × 10^9^ per L), 134 patients (32%) showed peripheral blood eosinophil ratio more than 5%. The eosinophil count higher than 1500 cells per μL were recorded in 13 (3%) patients.Table 1Baseline demographic and clinical characteristics of patients with IgG4-RD.Total (n = 425)Patients without eosinophilia (n = 338)Patients with eosinophilia (n = 87)P valuePeripheral blood eosinophil count (cells per μL)210 (100--420)170 (80--260)770 (610--1100)\<0.001Age (years)^\#^54 ± 1354 ± 1353 ± 150.442Male (%)60.4%57.1%73.3%0.007Disease duration (months)^\*^12(4--36)10(4--36)12(6--48)0.034Allergy history49.2%47.6%55.2%0.145IgG4-RD RI^\*^12 (7--16)11 (7--15)13 (10--17)\<0.001Numbers of organs involved3.31 ± 1.713.17 ± 1.633.86 ± 1.890.003HBG (g/L)^\#^134.2 ± 18.3134.2 ± 18.1134.3 ± 19.20.687PLT (×109/L)^\*^231 (195--280)231 (191--281)237 (206--278)0.254WBC (×10^9^/L)^\*^6.7 (5.6--8.0)6.5 (5.5--7.7)7.32 (5.90--9.03)\<0.001ESR (mm/h)^\*^18 (8--51)17 (8--44)34 (12--76)0.002CRP (mg/L)^\*^2.1 (0.8--7.6)2.3 (0.7--7.6)2.1 (1.3--7.4)0.342IgG (g/L)^\*^18.7 (14.6--24.7)18.1 (14.2--23.3)24.1 (16.4--32.6)\<0.001IgA (g/L)^\*^2.06 (1.39--2.75)2.14 (1.54--2.85)1.54 (0.96--2.13)\<0.001IgM (g/L)^\*^0.77 (0.55--1.22)0.81 (0.57--1.24)0.70 (0.48--1.05)0.094IgG1 (g/L)^\*^9.14 (7.45--11.00)9.06 (7.30--10.60)9.68 (7.65--13.10)0.009IgG2 (g/L)^\*^5.73 (4.42--7.58)5.88 (4.56--7.64)5.27 (3.75--7.18)0.022IgG3 (g/L)^\*^0.45 (0.24--0.86)0.42 (0.23--0.81)0.55 (0.31--0.98)0.012IgG4 (g/L)^\*^7.72 (3.18--17.50)6.50 (2.74--14.38)17.00 (5.60--31.55)\<0.001IgG4/IgG^\*^0.34 (0.17--0.53)0.31 (0.16--0.48)0.49 (0.25--0.61)\<0.001IgE (KU/L)^\*^347 (126--752)302 (119--662)480 (157--1164)0.010C3 (g/L)^\*^0.94 (0.75--1.11)0.96 (0.79--1.11)0.79 (0.58--1.15)0.088C4 (g/L)^\*^0.17 (0.12--0.24)0.18 (0.13--0.24)0.12 (0.05--0.19)\<0.001HGB, hemoglobin; PLT, platelet cell; WBC, white blood cell; GC mono, glucocorticoids monotherapy; GC & IM, glucocorticoids combined immunosuppressants therapy; IM mono, immunosuppressants monotherapy; TCM, traditional Chinese medicine; \*Values are median (IQR); ^\#^Values are Mean ± Standard Deviation.

Patients with eosinophilia were more likely to be male (73.3% vs. 57.1%, *P* = 0.007) and with longer disease duration \[12(6--48) vs. 10(4--36), *P* = 0.034\] (Table [1](#Tab1){ref-type="table"}).

Patients with eosinophilia exhibited more organ involvement and higher serum IgG4 level {#Sec4}
---------------------------------------------------------------------------------------

Patients with eosinophilia had higher incidence of dacryoadenitis (61.9% vs 16.4%, *P* = 0.014), submandibular sialadenitis (65.9% vs 49.5%, *P* = 0.007), lymphadenopathy (55.3% vs 42.0%, *P* = 0.037) and skin rash (7.4% vs 2.7%, *P* = 0.034) (Fig. [1A](#Fig1){ref-type="fig"}), as well as higher IgG4-RD RI and more organ involvement (*P* \< 0.05, Table [1](#Tab1){ref-type="table"}). Interestingly, there was no significant difference in the incidence of allergic diseases between patients with and without eosinophilia (Table [1](#Tab1){ref-type="table"}). In the laboratory inspection, patients with eosinophilia showed higher peripheral WBC, ESR, serum IgG, IgG1, IgG3, IgG4, IgE, and IgG4/IgG ratio, while lower serum IgA, IgG2 and C4 level (*P* \< 0.05, Table [1](#Tab1){ref-type="table"}).Figure 1Organs involvement and outcome of patients with and without eosinophilia. (**A**) Organ involvement of the two groups of patients. (**B**) Disease remission rate an[d]{.ul} recurrence rate. (**C--E**) Changes of peripheral blood eosinophil count, serum IgG4, IgG4-RI of the two groups of patients during follow-up. IgG4-RD RI, IgG4-RD responder index. \**P* \< 0.05; \*\**P* \< 0.01.

Peripheral eosinophil counts correlated to disease burden in IgG4-RD patients {#Sec5}
-----------------------------------------------------------------------------

Correlation analysis revealed that peripheral eosinophil counts were positively correlated with disease duration, numbers of organs involved, and IgG4-RD RI (Table [2](#Tab2){ref-type="table"}). Besides, blood eosinophil counts were also positively related to peripheral WBC, ESR, IgG, IgG1, IgG3, IgG4, IgE, and IgG4/IgG ratio, whereas negatively correlated to IgA, IgM, IgG2 and C4, as showed in Table [2](#Tab2){ref-type="table"}. All these indicate that peripheral eosinophil counts were associated with disease burden in IgG4-RD patients.Table 2Correlations between peripheral blood eosinophil count and clinical indicators.ParametersPeripheral blood eosinophil countSpearman rP valueAge (years)0.0050.922Disease duration (months)0.1400.006Numbers of organs involved0.1530.002IgG4-RD RI0.1690.001WBC (×10^9^/L)0.190\<0.001ESR (mm/h)0.1040.040CRP (mg/L)0.0120.827IgG (g/L)0.240\<0.001IgA (g/L)−0.244\<0.001IgM (g/L)−0.1280.010IgG1 (g/L)0.1020.042IgG2 (g/L)−0.1080.030IgG3 (g/L)0.1150.021IgG4 (g/L)0.335\<0.001IgG4/IgG0.320\<0.001IgE (KU/L)0.1790.002C3 (g/L)−0.1060.094C4 (g/L)−0.2000.002

Patients with eosinophilia were more liable to undergo disease relapse {#Sec6}
----------------------------------------------------------------------

In the overall 425 patients, 46 patients (10.8%) were untreated and under observation, 110 patients (25.9%) received glucocorticoids monotherapy (GC mono), 60 patients (14.1%) received immunosuppressants monotherapy (IM mono), 208 patients (48.9%) received combination therapy with GC and IM, 1 patient (0.2%) chose traditional Chinese medicine treatment. Treatment options displayed no significant difference between the two groups.

Remission rates were evaluated six months after initiating remission induction treatment with GC or GC combined IM. It seemed that patients with eosinophilia tend to have a lower remission rate, but the difference was not statistically significant \[83.8% (160/191) vs. 72.9% (35/48), *P* = 0.096\] (Fig. [1B](#Fig1){ref-type="fig"}). IgG4-RD RI dropped by half or more at the 6^th^- month follow-up in the two groups were 92.2% (202/219) and 89.7% (52/58), respectively (*P* = 0.526).

Patients were followed up for 25 ± 15 months. The disease relapse rate was calculated in 315 patients who were followed up for three months or longer. The final results showed that the total recurrence rate was 19.7% (62/315), and patients with eosinophilia showed a higher relapse rate than patients without eosinophilia \[28.6% (20/70) vs. 17.1% (42/245), *P* = 0.034\] (Fig. [1A](#Fig1){ref-type="fig"}). The mean time of recurrence was around 12th (7--24) month, no significant difference was found between two groups \[11 (6--24) month vs. 12 (7--27) month, *P* = 0.509\]. Patients with hypereosinophilia (\>1500 cells per μL) displayed a trend of higher recurrence rate than patients with blood eosinophil count range from 500 to 1500 cells per μL, but the difference was not significant \[33.3% (4/12) vs. 27.6% (16/58), *P* = 0.768\]. A lower proportion of patients with eosinophilia had a blood IgG4 level reaching the normal range at the 3rd, 6th, 12th-month follow-up (Table [3](#Tab3){ref-type="table"}).Table 3Different levels of serum IgG4 during follow-up.Patients without eosinophiliaPatients with eosinophiliaP value**Serum IgG4 at baseline**Normal (\<1.35 g/L)4.7% (16/338)3.4% (3/87)0.625**Serum IgG4 at 1** ^**st**^ **month follow-up**Normal (\<1.35 g/L)17.7% (29/164)13.5% (5/37)0.430Decrease by 50% or more\*47% (77/164)54.1% (20/37)0.626**Serum IgG4 at 3** ^**rd**^ **month follow-up**Normal (\<1.35 g/L)34.7% (77/222)15.8% (9/57)0.003Decrease by 50% or more\*72.5% (161/222)80.7% (46/57)0.317**Serum IgG4 at 6** ^**th**^ **month follow-up**Normal (\<1.35 g/L)40.2% (78/194)14.6% (7/48)0.001Decrease by 50% or more\*70.1% (136/194)81.3% (39/48)0.122**Serum IgG4 at 12** ^**th**^ **month follow-up**Normal (\<1.35 g/L)37.8% (65/172)19.1% (9/47)0.011Decrease by 50% or more\*73.8% (127/172)70.2% (33/47)0.620\*As compared to serum IgG4 levels at baseline.

During the follow-up period, patients with eosinophilia improved significantly, and the peripheral blood eosinophils fell to normal range (\<500/μL) in 92.6% (50/54), 80.9% (38/47) and 83% (35/42) at the 3rd, 6th, 12th-month follow-up, respectively. While three patients without eosinophilia at baseline assessment developed eosinophilia during follow-up, and these patients showed no signs of disease relapse (Fig. [1C](#Fig1){ref-type="fig"}). The trends of serum IgG4 and IgG4-RD RI levels during follow-up were shown in Fig. [1D,E](#Fig1){ref-type="fig"}. Univariable logistic regression analysis revealed that eosinophilia at baseline and IgA \< 0.7 g/L (lower limit of the normal range) were two risk factors for sustained eosinophilia at the 12th-month follow-up (Table [4](#Tab4){ref-type="table"}). Serum IgG4 level at 12 months was positively correlated with blood eosinophil count at 12 months (r = 0.314, *P* \< 0.001). Comparing patients with different treatment choices, we found that glucocorticoid-based therapy seemed to be more conducive to peripheral blood eosinophil counts declination (Fig. [2](#Fig2){ref-type="fig"}).Table 4Univariable logistic regression analysis of risk factors for eosinophilia at 12^th^ month follow-up.Eosinophilia at 12^th^ month follow-upOR (95% CI)P valueFemale sex0.18 (0.02--1.43)0.105Allergy history0.86 (0.24--3.06)0.812Involved organ number1.25 (0.75--2.10)0.394Eosinophilia at baseline9.80 (2.41--39.81)0.001Elevated ESR1.43 (0.39--5.25)0.590Elevated WBC3.91 (0.93--16.44)0.063Elevated IgG1.33 (0.32--5.51)0.691Elevated IgG1 level1.24 (0.25--6.26)0.794Elevated IgG2 level0.58 (0.14--2.30)0.434Elevated IgG3 level1.94 (0.38--9.92)0.428IgA below LLN5.79 (1.03--32.45)0.046Complement below LLN\*4.65 (0.47--46.28)0.190\*LLN, lower limit of the normal range.Figure 2Changes in peripheral blood eosinophil (PBE) counts during follow-up, grouped according to treatment options. (**A--D**) display peripheral blood eosinophil counts at baseline, the third month follow-up, the sixth-month follow-up, and the 12th month follow-up, respectively. Bars represent median and interquartile ranges. GC mono, glucocorticoids monotherapy; GC & IM, combination therapy with glucocorticoids and immunosuppressants; IM mono, immunosuppressants monotherapy.

Discussion {#Sec7}
==========

IgG4 related disease (IgG4-RD) is a fibroinflammatory disease with systemic involvement. The pathogenesis of IgG4-RD remains mostly unknown. Many studies have described blood and tissue eosinophilia in patients with IgG4-RD^[@CR5]--[@CR11]^. However, most of them didn't describe the comparison between patients with and without eosinophilia. Only one study found that the presence of eosinophilia did not result in a different clinical pattern in patients with type 1 autoimmune pancreatitis^[@CR11]^. However, in their analysis, they only included patients with single-organ involvement, not systemic IgG4-RD. Hence, the clinical significance of eosinophilia in IgG4-RD is still unclear.

In this study, based on the largest cohort of IgG4-RD patients in China, we report that 20% of patients had eosinophilia. Patients with and without eosinophilia showed different clinical patterns in terms of organ involvement and laboratory findings. Patients with eosinophilia seemed to have a higher disease burden as indicated by elevated serum IgG, IgG4, ESR, and more organs involved, and higher IgG4-RD RI score. As in an IgG4-RD grouping analysis which reported by Wallace *et al*.^[@CR17]^, patients were divided into four groups, Group 4 was male-dominated, characterized by classic Mikulicz syndrome with systemic involvement, showing the highest serum IgG4 levels, but they did not give the comparison of blood eosinophil counts among groups. We previously revealed that systemic IgG4-RD patients with dacryoadenitis and sialadenitis (IgG4-DS) and internal organs involvement had higher serum IgG4 levels and a higher rate of eosinophilia than patients with only IgG4-DS^[@CR18]^. Patients with only IgG4-DS are more likely to ignore the disease, thus delay the diagnosis and treatment until systemic symptoms occurred, this could be speculated by longer disease duration at diagnosis in patients with eosinophilia. When we independently analyzed the organ involvement number apart from lacrimal glands, salivary glands, and lymph nodes, there was no significant difference between the two groups.

Allergic disorders are common causes of reactive eosinophilia^[@CR19]^. However, there was no statistically significant difference in the incidence of allergic disease between patients with and without eosinophilia, indicating that eosinophilia is independent of allergies in IgG4-RD patients, which was consistent with the results reported by Della-Torre *et al*.^[@CR10]^ and Sah *et al*.^[@CR11]^. Wallace *et al*.^[@CR20]^ have found that elevated eosinophil count in the baseline was an independent predictor of disease relapse; also, our previous study showed eosinophilia was a risk factor for remission induction failure^[@CR21]^. Here, we confirmed that IgG4-RD patients with peripheral eosinophilia were more liable to disease relapse.

We found here that peripheral eosinophil counts in IgG4-RD patients were positively correlated with serum IgG4 and disease burden. In addition, serum IgG4 level at 12 months was also positively correlated with the blood eosinophil count at 12 months. IgG4-RD exhibited activated Th2 response^[@CR22]--[@CR26]^, and this may be responsible for eosinophilia in IgG4-RD^[@CR19]^. Otherwise, activated eosinophils release cytokines^[@CR2]^, which can promote the production of IgG4^[@CR27]^. Although it remains unclear that IgG4 plays a pathogenic or protective role in IgG4-RD^[@CR28]^, these indicate that eosinophils participate in the pathogenesis of IgG4-RD.

Both CRP and ESR are used to predict inflammatory conditions. ESR level can be affected by factors other than inflammation, such as levels of serum fibrinogen and immunoglobulins. We believe that the difference of ESR levels between the two groups was mainly due to the different distribution of serum IgG and IgG4, as patients with eosinophilia had higher serum IgG, IgG4, while with a similar level of CRP compared to patients with normal eosinophil counts. Patients with eosinophilia showed male predominance, as reported that peripheral blood eosinophil count is skewed according to gender, males usually hav[e]{.ul} higher eosinophil count^[@CR29],[@CR30]^.

Activation of eosinophils led to the production of transforming growth factor (TGF)-β^2^, and the latter was reported to participate in the pathogenesis of fibrosis. Fibrosis occurred in the affected organs of advanced IgG4-RD patients. We found that peripheral eosinophil counts in IgG4-RD patients were positively correlated to treatment-free disease duration; patients with eosinophilia showed longer disease duration. These indicate that eosinophilia may occur in the advanced stage of IgG4-RD, and may participate in the fibrosis of affected tissues.

To date, several treatment approaches, including glucocorticoids, myelosuppressive drugs, leukotriene antagonists, tyrosine kinase inhibitors, IFN-α, and anti-IL-5 antibodies, have been described for eosinophilia. Although the role of eosinophilia in the pathogenesis of IgG4-RD is debatable, we found that IgG4-RD patients with peripheral eosinophilia tend to be more liable to disease relapse, this raises the possibility of anti-eosinophil therapy such as monoclonal antibody to IL-5 for IgG4-RD patients with recurrent disease.

Our study has some limitations. This is a single-center study, which may cause bias in interpreting results. Only two patients with eosinophilia had done bone marrow biopsy at baseline and showed elevated bone marrow eosinophils. No further tests for the myeloid or lymphocytic variant hypereosinophilic syndrome (HES) had performed. As proposed by Chen *et al*.^[@CR31]^, the diagnosis of idiopathic HES need to rule out IgG4-RD, the differential diagnosis between IgG4-RD and myeloid or lymphocytic variant HES need careful consideration of clinical and laboratory manifestation.

In conclusion, peripheral eosinophilia was associated with a different clinical pattern of IgG4-RD. Eosinophil may play an important role in the development of IgG4-RD, especially in patients with longer disease duration and probably pronounced fibrotic lesion. Our findings paved the way for identifying the role of eosinophils in the pathogenesis of IgG4-RD.

Methods {#Sec8}
=======

Patients and study design {#Sec9}
-------------------------

A multidisciplinary collaborative prospective cohort study of IgG4-RD and Mimicry patients has been conducted in Peking Union Medical College Hospital (PUMCH, Beijing, China) since January 2011, registered on ClinicalTrials.gov (ID: NCT01670695). Patients were diagnosed with IgG4-RD according to the 2011 comprehensive diagnostic criteria for IgG4-RD^[@CR32]^. Fifty-one patients who had a history of other rheumatic diseases, infectious diseases, or malignancies, which may cause eosinophilia, were excluded. As of August 2018, 425 newly diagnosed IgG4-RD patients were enrolled in this study.

Eosinophilia in the peripheral blood was defined as eosinophil count greater than 500 per μL (0.5 × 10^9^ per L). We divided the patients into two groups according to whether there was eosinophilia. According to the Allergy Definition of the European Society for Allergy and Clinical Immunology^[@CR33]^: (1) a history of clinical allergic diseases; (2) a positive skin test or an increase in serum allergen-specific IgE, while satisfying the definition of both as an allergy. Patients with newly diagnosed IgG4-RD were classified as allergic and non-allergic. All patients visited the doctors regularly at 1st and every 3 to 6 months intervals follow up.

Clinical data and laboratory parameters including complete blood count (CBC), liver and renal function tests, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum immunoglobulin levels, IgG subclasses, and total IgE levels were collected. Organ involvements were defined by physical examination and imaging findings, including computed tomography (CT), or magnetic resonance imaging (MRI), or Positron Emission Tomography/Computed Tomography (PET-CT). Disease activity was assessed by the IgG4-RD responder index (RI)^[@CR34]^.

Outcomes {#Sec10}
--------

Disease remission and relapse were described as before^[@CR21]^. Briefly, the initial 6th -months of treatment was defined as the remission induction stage, and remission was defined as fulfilling each of the following after 6-month treatment: (1) ≥50% decline in the IgG4-RD RI; (2) GC tapered to maintenance dose (prednisone ≤10 mg/day); and (3) no relapse during GC tapering (within 6 months). Clinical symptoms recurred, or imaging findings worsened with or without IgG4 level increased were considered as disease relapse in patients who had a follow-up period of 3 months or longer.

Statistical analysis {#Sec11}
--------------------

Continuous variables are described in mean and standard deviation (SD) or median and interquartile range (IQR) according to the data distribution. Comparisons between the two groups were performed using Student's *t*-test or the appropriate non-parametrical test, depending on normal or non-normal data distribution. Categorical variables were expressed as percentages, and *χ*^2^-test was used for comparisons. Fisher's exact test was used when one or more expected frequencies were less than 5. Correlation between two continuous non-normal variables was analyzed using Spearman's rank correlation. Univariate logistic regression was used to predict risk factors for eosinophilia at 12 months follow-up. Statistical analysis was performed by SPSS version 24.0 and Graphpad Prism version 7.0. A *P*-value \< 0.05 was considered statistically significant.
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